Aurobindo Pharma receives USFDA’s nod to manufacture Ondansetron Injection

24 Dec 2012 Evaluate

Aurobindo Pharma has received final approvals from the US Food & Drug Administration (USFDA) to manufacture and market Ondansetron Injection USP 2rng/mL packaged in 40mg/20mL Multiple-dose Vials (ANDA 202599) and Ondansetron Injection USP 2mg/mL packaged in 4mg/2mL Single-dose Vials, Preservative-free (ANDA 202600).

Importantly, these are the first ANDA’s to be approved out of Unit IV formulation facility in Hyderabad, India for manufacturing general liquid injectable and ophthalmic products and will be marketed and sold by  Aurobindo's wholly owned subsidiary AuroMedics Pharma LLC. Further, these products are ready for launch.

The approved Ondansetron Injections are the generic equivalent of GlaxoSmithKline’s Zofran Injection and indicated for prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy or postoperative nausea and/or vomiting.

Aurobindo Pharma, headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil.

Aurobindo Pharma Share Price

1240.70 -14.70 (-1.17%)
20-Dec-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1808.50
Dr. Reddys Lab 1342.45
Cipla 1472.45
Lupin 2147.55
Zydus Lifesciences 973.90
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.